Annals of Hematology

, Volume 93, Issue 7, pp 1193–1200 | Cite as

Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy

  • Chan Y. Cheah
  • Michael Dickinson
  • Michael S. Hofman
  • Anupkumar George
  • David S. Ritchie
  • H. Miles Prince
  • David Westerman
  • Simon J. Harrison
  • Kate Burbury
  • Max Wolf
  • Henry Januszewicz
  • Kirsten E. Herbert
  • Dennis A. Carney
  • Constantine Tam
  • John F. Seymour
Original Article

Abstract

The optimum follow-up of patients with transformed indolent lymphoma (TrIL) is not well defined. We sought to determine the utility of surveillance positron emission tomography-computed tomography (PET-CT) in patients with TrIL achieving complete metabolic remission (CMR) after primary therapy. We performed a retrospective analysis of patients with TrIL treated at Peter MacCallum Cancer Centre between 2002 and 2012 who achieved CMR after primary therapy who had ≥1 subsequent surveillance PET-CT. Of 55 patients with TrIL, 37 (67 %) received autologous stem cell transplantation as consolidation following chemoimmunotherapy. After a median follow-up of 34 (range 3–101) months, the actuarial 3-year progression-free (PFS) and overall survival (OS) were 77 % (95 %CI 62–86 %) and 88 % (75–94 %), respectively. Of 180 surveillance PET-CT scans, there were 153 true negatives, 4 false positives, 1 false negative, 7 indeterminate and 15 true positives. Considering indeterminate scans as false positives, the specificity of PET-CT for detecting relapse was 94 %, sensitivity was 83 %, positive predictive value was 63 % and negative predictive value was 98 %. All seven subclinical (PET detected) relapses were of low-grade histology; in contrast, all nine relapses with diffuse large B cell lymphoma (DLBCL) were symptomatic. In our cohort of patients with TrIL achieving CMR, PET-CT detected subclinical low-grade relapses but all DLBCL relapses were accompanied by clinical symptoms. Thus, surveillance imaging of patients with TrIL achieving CMR is of limited clinical benefit. PET-CT should be reserved for evaluation of clinically suspected relapse.

Keywords

Transformed lymphoma Follow-up PET Surveillance imaging 

Supplementary material

277_2014_2040_MOESM1_ESM.docx (46 kb)
Supplementary Table 1(DOCX 46 kb)

References

  1. 1.
    Montoto S, Fitzgibbon J (2011) Transformation of indolent B-cell lymphomas. J Clin Oncol 29(14):1827–1834. doi:10.1200/JCO.2010.32.7577 PubMedCrossRefGoogle Scholar
  2. 2.
    Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 26(32):5165–5169. doi:10.1200/JCO.2008.16.0283 PubMedCrossRefGoogle Scholar
  3. 3.
    Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, Bryon PA, Coiffier B (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15(4):1587–1594PubMedGoogle Scholar
  4. 4.
    Gine E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martinez A, Colomo L, Campo E, Montserrat E, Lopez-Guillermo A (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17(10):1539–1545. doi:10.1093/annonc/mdl162 PubMedCrossRefGoogle Scholar
  5. 5.
    Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, Vinnicombe S, Waters R, Rohatiner AZ, Lister TA (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25(17):2426–2433. doi:10.1200/JCO.2006.09.3260 PubMedCrossRefGoogle Scholar
  6. 6.
    Al-Tourah AJ, Savage KJ, Gill KK, Klasa RJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM (2007) Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. ASH Annual Meeting Abstracts 110 (11):790Google Scholar
  7. 7.
    Villa D, Crump M, Keating A, Panzarella T, Feng B, Kuruvilla J (2013) Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. Ann Oncol 24(6):1603–1609. doi:10.1093/annonc/mdt029 PubMedCrossRefGoogle Scholar
  8. 8.
    Cabanillas F, Velasquez WS, Hagemeister FB, McLaughlin P, Redman JR (1992) Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood 79(4):1024–1028PubMedGoogle Scholar
  9. 9.
    Larouche JF, Berger F, Chassagne-Clement C, Ffrench M, Callet-Bauchu E, Sebban C, Ghesquieres H, Broussais-Guillaumot F, Salles G, Coiffier B (2010) Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 28(12):2094–2100. doi:10.1200/jco.2009.24.5860 PubMedCrossRefGoogle Scholar
  10. 10.
    Wong E, Dickinson M (2012) Transformation in follicular lymphoma: biology, prognosis, and therapeutic options. Curr Oncol Rep 14(5):424–432. doi:10.1007/s11912-012-0258-4 PubMedCrossRefGoogle Scholar
  11. 11.
    Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Group ObotEGW (2011) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(suppl 6):vi59–vi63. doi:10.1093/annonc/mdr388 PubMedGoogle Scholar
  12. 12.
    Tilly H, Dreyling M (2010) Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v172–v174. doi:10.1093/annonc/mdq203 PubMedCrossRefGoogle Scholar
  13. 13.
    Cheah CY, Hofman MS, Dickinson M, Wirth A, Westerman D, Harrison SJ, Burbury K, Wolf M, Januszewicz H, Herbert K, Prince HM, Carney DA, Ritchie DS, Hicks RJ, Seymour JF (2013) Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109(2):312–317. doi:10.1038/bjc.2013.338 PubMedCrossRefGoogle Scholar
  14. 14.
    Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578. doi:10.1200/jco.2006.08.2305 PubMedCrossRefGoogle Scholar
  15. 15.
    Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 50(8):1257–1260. doi:10.1080/10428190903040048 PubMedCrossRefGoogle Scholar
  16. 16.
    Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD (2006) Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 17(6):909–913. doi:10.1093/annonc/mdl049 PubMedCrossRefGoogle Scholar
  17. 17.
    Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, MacDonald DA, Buckstein R, Lee C, Alzahrani M, Rubinger M, Foley R, Xenocostas A, Sabloff M, Muccilli A, Chua N, Couture F, Larouche JF, Cohen S, Connors JM, Ambler K, Al-Tourah A, Ramadan KM, Kuruvilla J (2013) Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol 31(9):1164–1171. doi:10.1200/JCO.2012.44.0693 PubMedCrossRefGoogle Scholar
  18. 18.
    Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, Taghipour G, Schmitz N, Goldstone AH, European Bone Marrow Transplant Lymphoma Working P (2001) High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19(3):727–735PubMedGoogle Scholar
  19. 19.
    Elis A, Blickstein D, Klein O, Eliav-Ronen R, Manor Y, Lishner M (2002) Detection of relapse in non-Hodgkin’s lymphoma: role of routine follow-up studies. Am J Hematol 69(1):41–44PubMedCrossRefGoogle Scholar
  20. 20.
    Guppy AE, Tebbutt NC, Norman A, Cunningham D (2003) The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma 44(1):123–125. doi:10.1080/1042819021000040323 PubMedCrossRefGoogle Scholar
  21. 21.
    Weeks JC, Yeap BY, Canellos GP, Shipp MA (1991) Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 9(7):1196–1203PubMedGoogle Scholar
  22. 22.
    Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, Tsai DE, Nasta SD, Elstrom RL, Goldstein SC, Downs LH, Mangan PA, Cunningham KA, Hummel KA, Gimotty PA, Siegel DL, Glatstein E, Stadtmauer EA (2005) Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant 36(11):955–961. doi:10.1038/sj.bmt.1705178 PubMedCrossRefGoogle Scholar
  23. 23.
    Chen CI, Crump M, Tsang R, Stewart AK, Keating A (2001) Autotransplants for histologically transformed follicular non-Hodgkin’s lymphoma. Br J Haematol 113(1):202–208PubMedCrossRefGoogle Scholar
  24. 24.
    Hamadani M, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM (2008) High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol 81(6):425–431. doi:10.1111/j.1600-0609.2008.01146.x PubMedCrossRefGoogle Scholar
  25. 25.
    Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P, Hopkins H, Hutton B, McDiarmid S, Huebsch LB (2007) A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 13(8):956–964. doi:10.1016/j.bbmt.2007.04.009 PubMedCrossRefGoogle Scholar
  26. 26.
    Dickinson M (2012) Is autologous stem cell transplantation for transformed follicular lymphoma still justifiable? Leuk Lymphoma 53(5):754–755. doi:10.3109/10428194.2012.656637 PubMedCrossRefGoogle Scholar
  27. 27.
    Tam CS, Herschtal A, Dickinson M, George A, Seymour JF (2013) Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era. J Clin Oncol. doi:10.1200/jco.2013.50.2245 PubMedCentralGoogle Scholar
  28. 28.
    Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB (2013) Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol 160(5):608–617. doi:10.1111/bjh.12176 PubMedCrossRefGoogle Scholar
  29. 29.
    Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW (2012) High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma 53(5):830–835. doi:10.3109/10428194.2011.631637 PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PM, Stathis A, Moccia AA, Mazzucchelli L, Bertoni F, Ghielmini M, Cavalli F, Zucca E (2012) Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 157(2):188–196. doi:10.1111/j.1365-2141.2012.09054.x PubMedCrossRefGoogle Scholar
  31. 31.
    Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. doi:10.1200/jco.2012.48.3990 Google Scholar
  32. 32.
    Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenholder M, Ostenstad B, Fluge O, Delabie J, Aarset H, Liestol K, Holte H (2011) High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol 152(5):600–610. doi:10.1111/j.1365-2141.2010.08519.x Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Chan Y. Cheah
    • 1
    • 3
  • Michael Dickinson
    • 1
    • 3
  • Michael S. Hofman
    • 2
    • 3
  • Anupkumar George
    • 1
  • David S. Ritchie
    • 1
    • 3
  • H. Miles Prince
    • 1
    • 3
    • 4
    • 5
  • David Westerman
    • 1
  • Simon J. Harrison
    • 1
    • 3
  • Kate Burbury
    • 1
  • Max Wolf
    • 1
    • 3
  • Henry Januszewicz
    • 1
  • Kirsten E. Herbert
    • 1
    • 4
  • Dennis A. Carney
    • 1
    • 3
  • Constantine Tam
    • 1
    • 3
  • John F. Seymour
    • 1
    • 3
  1. 1.Department of HaematologyPeter MacCallum Cancer CentreEast MelbourneAustralia
  2. 2.Centre for Cancer ImagingPeter MacCallum Cancer CentreEast MelbourneAustralia
  3. 3.Sir Peter MacCallum Department of OncologyUniversity of MelbourneMelbourneAustralia
  4. 4.Cabrini Medical CentreMelbourneAustralia
  5. 5.Monash UniversityMelbourneAustralia

Personalised recommendations